Evofem Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Income (Loss)
(In thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net income (loss) | $(2,365) | $66,005 | $(5,823) | $55,093 |
| Other comprehensive income (loss): | ||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | (1,069) | (455) | (1,001) | 23,373 |
| Reclassification adjustment related to debt extinguishment | 143 | (73,187) | 143 | (73,187) |
| Comprehensive income (loss) | $(3,291) | $(7,637) | $(6,681) | $5,279 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.